Trial Profile

US Post-Marketing Retrospective Observational Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)(TM)

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 25 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Moxetumomab pasudotox (Primary)
Indications Hairy cell leukaemia
Focus Adverse reactions
Acronyms LUMOXITI TM; PROXY
Sponsors AstraZeneca; Innate Pharma

Most Recent Events

20 Apr 2023 Status changed from recruiting to discontinued due to lack of recruitment.
19 Apr 2022 Planned number of patients changed from 80 to 2.
19 Apr 2022 Planned End Date changed from 1 Sep 2023 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com